A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors

Launched by HUASHAN HOSPITAL · Nov 19, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at new imaging methods called PET/CT scans, which use special substances to help doctors see certain types of tumors in the body. Specifically, the study focuses on tumors that express a protein called CD70, which is found in kidney cancer and lymphomas. Researchers want to determine how effective these imaging methods are in diagnosing these types of cancer.

To participate in the study, individuals must be between 18 and 65 years old and have a confirmed diagnosis of kidney cancer or lymphoma. Participants need to be willing to sign a consent form and follow the study's guidelines. It’s important to note that people with severe liver or kidney problems, recent major surgeries, or those who have taken part in other clinical trials recently may not be eligible. Those who join the study can expect to undergo PET/CT scans to help researchers understand how well these new imaging agents work in identifying cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Be between 18 and 65 years of age and of either sex.
• • 2. Affected with renal cancer or lymphoma confirmed by puncture or surgical pathology.
• • 3. Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
• • 4. Willingness and ability to cooperate with all programs of this study.
• Exclusion Criteria:
• * Subjects meeting any of the following criteria will be excluded from the study:
• • 1. Severe hepatic and renal insufficiency;
• • 2. Targeted therapy prior to radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range;
• • 3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
• • 4. History of serious surgery in the last month.
• • 5. Those who have participated in other clinical trials during the same period.